The added value of different biomarkers to the Revised Cardiac Risk Index to predict major adverse cardiac events and all‐cause mortality after noncardiac surgery

不同生物标志物对修订版心脏风险指数的附加价值,可用于预测非心脏手术后的主要不良心脏事件和全因死亡率

阅读:2

Abstract

This is a protocol for a Cochrane Review (Prognosis). The objectives are as follows: The primary objective of this Cochrane Review is to quantify the added predictive value of several biomarkers to the Revised Cardiac Risk Index (RCRI) and to estimate the predictive performance of biomarkers compared to the RCRI alone to predict major adverse cardiac events (MACEs) and all‐cause mortality in patients undergoing noncardiac surgery. Table 1 represents the PICOTS of the review based on the CHARMS checklist (Moons 2014). Table 1. PICOTS of the review based on the CHARMS checklist Investigation of sources of heterogeneity between studies We will assess sources of heterogeneity based on the population, outcome definitions and prediction horizons. The RCRI was originally developed for a noncardiac, nonvascular surgical population to predict in‐hospital MACEs. However, the RCRI has also been externally validated in vascular surgical patients (Gillmann 2014; Scrutinio 2014), in which the predictive performance was found to be moderate (Ford 2010). In addition, prediction horizons vary between studies from in‐hospital to long‐term events (e.g. postoperative 1‐year all‐cause mortality). Finally, the composition of items that defines MACEs varies among different studies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。